Porton Pharma Solutions Ltd. provides contract development and manufacturing organization (CDMO) solutions for small molecules, tides, biologics, and conjugates from pre-clinical to commercial in China and internationally. It has a strategic collaboration with Aojin Life Sciences to advance XDC conjugate drugs; and strategic partnership with Dragon Sail Pharmaceutical to build a new ecosystem for ADC drug development, production, and supply chain. It also offers crystallization, bio catalysis, metal catalysis, flow chemistry, prep-chromatography, and milling. Porton Pharma Solutions Ltd. was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd. in January 2018. The company was incorporated in 2005 and is headquartered in Chongqing, China.
Research context
Porton Pharma Solutions Ltd appears in PyInvesting’s Shenzhen Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CNY
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Porton Pharma Solutions Ltd is currently in a long term uptrend where the price is trading 55.2% above its 200 day moving average.
From a valuation standpoint, the stock is 43.3% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 13.8.
Porton Pharma Solutions Ltd's total revenue rose by 24.3% to $584M since the same quarter in the previous year.
Its net income has increased by 71.4% to $85M since the same quarter in the previous year.
Finally, its free cash flow fell by 64.5% to $37M since the same quarter in the previous year.
Based on the above factors, Porton Pharma Solutions Ltd gets an overall score of 3/5.